William Jacob Savage Sells 14,183 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) insider William Jacob Savage sold 14,183 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $65.45, for a total transaction of $928,277.35. Following the completion of the transaction, the insider now directly owns 40,405 shares of the company’s stock, valued at approximately $2,644,507.25. The trade was a 25.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

William Jacob Savage also recently made the following trade(s):

• On Friday, November 15th, William Jacob Savage sold 9,158 shares of Disc Medicine stock. The shares were sold at an average price of $59.64, for a total transaction of $546,183.12.

Disc Medicine Trading Up 3.0 %

IRON opened at $64.55 on Thursday. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of -16.26 and a beta of 0.60. The stock has a fifty day moving average price of $53.08 and a 200-day moving average price of $46.79. Disc Medicine, Inc. has a 12 month low of $25.60 and a 12 month high of $77.60.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.89) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.15. On average, equities research analysts forecast that Disc Medicine, Inc. will post -4.05 EPS for the current year.

Wall Street Analysts Forecast Growth

IRON has been the topic of several analyst reports. Wedbush reiterated an “outperform” rating and set a $83.00 price target (up from $75.00) on shares of Disc Medicine in a report on Tuesday, November 12th. Jefferies Financial Group assumed coverage on Disc Medicine in a research note on Wednesday, October 23rd. They set a “buy” rating and a $89.00 price target for the company. Scotiabank upped their price objective on Disc Medicine from $62.00 to $70.00 and gave the company a “sector outperform” rating in a research report on Tuesday, November 5th. Raymond James upgraded Disc Medicine from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $66.00 to $110.00 in a research report on Monday, November 4th. Finally, Wells Fargo & Company began coverage on shares of Disc Medicine in a research note on Thursday, August 22nd. They set an “overweight” rating and a $75.00 price target for the company. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $85.80.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in IRON. Amalgamated Bank raised its position in Disc Medicine by 76.9% during the 2nd quarter. Amalgamated Bank now owns 568 shares of the company’s stock worth $26,000 after buying an additional 247 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Disc Medicine by 45.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock valued at $54,000 after acquiring an additional 337 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Disc Medicine in the second quarter valued at approximately $129,000. Quest Partners LLC purchased a new position in shares of Disc Medicine during the 3rd quarter valued at approximately $131,000. Finally, Quantbot Technologies LP acquired a new position in Disc Medicine during the third quarter worth $146,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.